Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Review

Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy

Authors: Behdokht Bahrami, Mousa Mohammadnia-Afrouzi, Peyman Bakhshaei, Yaghoub Yazdani, Ghasem Ghalamfarsa, Mehdi Yousefi, Sanam Sadreddini, Farhad Jadidi-Niaragh, Mohammad Hojjat-Farsangi

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy. However, the specific drug delivery to cancer cells is an important issue which should be considered before designing new NPs for in vivo application. It has been shown that cancer cells over-express folate receptor (FR) in order to improve their growth. As normal cells express a significantly lower levels of FR compared to tumor cells, it seems that folate molecules can be used as potent targeting moieties in different nanocarrier-based therapeutic approaches. Moreover, there is evidence which implies folate-conjugated NPs can selectively deliver anti-tumor drugs into cancer cells both in vitro and in vivo. In this review, we will discuss about the efficiency of different folate-conjugated NPs in cancer therapy.
Literature
1.
Kazemi T, Younesi V, Jadidi-Niaragh F, Yousefi M. Immunotherapeutic approaches for cancer therapy: an updated review. Artificial Cells, Nanomed Biotechnol. 2015(0):1-11.
2.
Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, Majidi J, Yousefi M. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif cells, Nanomed Biotechnol. 2015(0):1-11.
3.
Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine. 2007;2(2):129–41.PubMedPubMedCentral
4.
Talekar M, Kendall J, Denny W, Garg S. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anti-Cancer Drugs. 2011;22(10):949–62.PubMed
5.
Conniot J, Silva JM, Fernandes JG, Silva LC, Gaspar R, Brocchini S et al. Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Frontiers Chem. 2014;2(105).
6.
Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284–93.PubMed
7.
Mansoori GA, Brandenburg KS, Shakeri-Zadeh A. A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancers. 2010;2(4):1911–28.PubMedPubMedCentral
8.
Ye W, Du J, Na R, Song Y, Mei Q, Zhao M. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One. 2014;9(5):e97358.PubMedPubMedCentral
9.
Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Del. 2013;2013(340315).
10.
Wang J, Yao K, Wang C, Tang C, Jiang X. Synthesis and drug delivery of novel amphiphilic block copolymers containing hydrophobic dehydroabietic moiety. J Mat Chem B. 2013;1(17):2324–32.
11.
Khoee S, Kavand A. Preparation, co-assembling and interfacial crosslinking of photocurable and folate-conjugated amphiphilic block copolymers for controlled and targeted drug delivery: smart armored nanocarriers. Eur J Med Chem. 2014;73:18–29.PubMed
12.
Miyata K, Christie RJ, Kataoka K. Polymeric micelles for nano-scale drug delivery. React Funct Polym. 2011;71(3):227–34.
13.
Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Del. 2006;3(1):139–62.
14.
Gao Z-G, Tian L, Hu J, Park I-S, Bae YH. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release. 2011;152(1):84–9.PubMedPubMedCentral
15.
Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog Polym Sci. 2007;32(8):962–90.
16.
Zhu J, Zhou Z, Yang C, Kong D, Wan Y, Wang Z. Folate-conjugated amphiphilic star-shaped block copolymers as targeted nanocarriers. J Biomed Mat Res Part A. 2011;97(4):498–508.
17.
Hami Z, Amini M, Ghazi-Khansari M, Rezayat SM, Gilani K. Doxorubicin-conjugated PLA-PEG-Folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation. DARU J Pharmaceut Sci. 2014;22(1):22–30.
18.
Scarano W, Duong HT, Lu H, De Souza PL, Stenzel MH. Folate conjugation to polymeric micelles via boronic acid ester to deliver platinum drugs to ovarian cancer cell lines. Biomacromolecules. 2013;14(4):962–75.PubMed
19.
Guo X, Shi C, Wang J, Di S, Zhou S. pH-triggered intracellular release from actively targeting polymer micelles. Biomaterials. 2013;34(18):4544–54.PubMed
20.
Wu W-C, Huang C-M, Liao P-W. Dual-sensitive and folate-conjugated mixed polymeric micelles for controlled and targeted drug delivery. React Funct Polym. 2014;81:82–90.
21.
Bae Y, Jang W-D, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol BioSyst. 2005;1(3):242–50.PubMed
22.
Liu S-Q, Wiradharma N, Gao S-J, Tong YW, Yang Y-Y. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials. 2007;28(7):1423–33.PubMed
23.
Song N, Ding M, Pan Z, Li J, Zhou L, Tan H, et al. Construction of targeting-clickable and tumor-cleavable polyurethane nanomicelles for multifunctional intracellular drug delivery. Biomacromolecules. 2013;14(12):4407–19.PubMed
24.
Prabaharan M, Grailer JJ, Steeber DA, Gong S. Thermosensitive micelles based on folate conjugated poly (N-vinylcaprolactam) block-poly (ethylene glycol) for tumor targeted drug delivery. Macromol Biosci. 2009;9(8):744–53.PubMed
25.
Syu WJ, Yu HP, Hsu CY, Rajan YC, Hsu YH, Chang YC, et al. Improved photodynamic cancer treatment by folate conjugated polymeric micelles in a KB xenografted animal model. Small. 2012;8(13):2060–9.PubMed
26.
Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Criti Rev Oncol/Hematol. 2013;88(3):504–13.
27.
Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211–9.PubMed
28.
Lindner J, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner B, et al. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol. 2014;26(1):95–100.PubMed
29.
Zhang L, Hou S, Mao S, Wei D, Song X, Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm. 2004;287(1):155–62.PubMed
30.
Zhao D, Zhao X, Zu Y, Li J, Zhang Y, Jiang R, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010;20(5):669–77.
31.
Hoffman RM, Bouvet M. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer. Expert Opin Pharmacother. 2015;16(7):943–7.PubMed
32.
Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99–105.PubMedPubMedCentral
33.
Ren K, Dusad A, Dong R, Quan L. Albumin as a delivery carrier for rheumatoid arthritis. J Nanomed Nanotechol. 2013;4(4):176.
34.
Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release. 2012;161(2):429–45.PubMed
35.
Hao H, Ma Q, Huang C, He F, Yao P. Preparation, characterization, and in vivo evaluation of doxorubicin loaded BSA nanoparticles with folic acid modified dextran surface. Int J Pharm. 2013;444(1):77–84.PubMed
36.
Shen Z, Li Y, Kohama K, Oneill B, Bi J. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacol Res. 2011;63(1):51–8.PubMed
37.
Su C, Li H, Shi Y, Wang G, Liu L, Zhao L, et al. Carboxymethyl-β-cyclodextrin conjugated nanoparticles facilitate therapy for folate receptor-positive tumor with the mediation of folic acid. Int J Pharm. 2014;474(1):202–11.PubMed
38.
Liang X, Sun Y, Liu L, Ma X, Hu X, Fan J, et al. Folate-functionalized nanoparticles for controlled ergosta-4, 6, 8 (14), 22-tetraen-3-one delivery. Int J Pharm. 2013;441(1):1–8.PubMed
39.
Zu Y, Zhang Y, Zhao X, Zhang Q, Liu Y, Jiang R. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folateconjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Int J Nanomedicine. 2009;4:321.PubMedPubMedCentral
40.
Martínez A, Muñiz E, Teijón C, Iglesias I, Teijón J, Blanco M. Targeting tamoxifen to breast cancer xenograft tumours: preclinical efficacy of folate-attached nanoparticles based on alginate-cysteine/disulphide-bond-reduced albumin. Pharm Res. 2014;31(5):1264–74.PubMed
41.
Yang R, An Y, Miao F, Li M, Liu P, Tang Q. Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo. Int J Nanomedicine. 2014;9:4231–43.PubMedPubMedCentral
42.
Zhang L, Hou S, Zhang J, Hu W, Wang C. Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles. Arch Pharm Res. 2010;33(8):1193–8.PubMed
43.
Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett. 2012;7(1):1–13.
44.
Jing Y, Dong-Yan H, Yousaf MZ, Yang-Long H, Song G. Magnetic nanoparticle-based cancer therapy. Chin Physics B. 2013;22(2):027506.
45.
Wang J, Chen Y, Chen B, Ding J, Xia G, Gao C, et al. Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice. Int J Nanomedicine. 2010;5:861–6.PubMedPubMedCentral
46.
Tang Q, An Y, Liu D, Liu P, Zhang D. Folate/NIR 797-conjugated albumin magnetic nanospheres: synthesis, characterisation, and in vitro and in vivo targeting evaluation. PLoS One. 2014;9(9):e106483.PubMedPubMedCentral
47.
Lu AH, Salabas EL, Schüth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed. 2007;46(8):1222–44.
48.
Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng. 2005;100(1):1–11.PubMed
49.
Majd MH, Barar J, Asgari D, Valizadeh H, Rashidi MR, Kafil V, et al. Targeted fluoromagnetic nanoparticles for imaging of breast cancer MCF-7 cells. Adv Pharmaceut Bull. 2013;3(1):189–95.
50.
Ma X, Gong A, Chen B, Zheng J, Chen T, Shen Z, et al. Exploring a new SPION-based MRI contrast agent with excellent water-dispersibility, high specificity to cancer cells and strong MR imaging efficacy. Colloids Surf B: Biointerfaces. 2014;126:44–9.PubMed
51.
Li J, Zheng L, Cai H, Sun W, Shen M, Zhang G, et al. Polyethyleneimine-mediated synthesis of folic acid-targeted iron oxide nanoparticles for in vivo tumor MR imaging. Biomaterials. 2013;34(33):8382–92.PubMed
52.
Shi J, Wang L, Gao J, Liu Y, Zhang J, Ma R, et al. A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials. 2014;35(22):5771–84.PubMed
53.
Wen J, Jiang S, Chen Z, Zhao W, Yi Y, Yang R, et al. Apoptosis selectively induced in BEL-7402 cells by folic acid-modified magnetic nanoparticles combined with 100 Hz magnetic field. Int J Nanomedicine. 2014;9:2043.PubMedPubMedCentral
54.
Majetich SA. Magnetic nanoparticles for biomedicine. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:4477–8.PubMed
55.
Varshosaz J, Hassanzadeh F, Sadeghi Aliabadi H, Nayebsadrian M, Banitalebi M, Rostami M. Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. BioMed Res Int. 2014;2014.
56.
Krais A, Wortmann L, Hermanns L, Feliu N, Vahter M, Stucky S, et al. Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. Nanomed: Nanotechnol, Biol Med. 2014;10(7):1421–31.
57.
Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108(6):2064–110.PubMed
58.
Sahoo B, Devi KSP, Dutta S, Maiti TK, Pramanik P, Dhara D. Biocompatible mesoporous silica-coated superparamagnetic manganese ferrite nanoparticles for targeted drug delivery and MR imaging applications. J Colloid Interface Sci. 2014;431:31–41.PubMed
59.
Wu W, He Q, Jiang C. Magnetic iron oxide nanoparticles: synthesis and surface functionalization strategies. Nanoscale Res Lett. 2008;3(11):397–415.PubMedPubMedCentral
60.
Guan Y-Q, Zheng Z, Huang Z, Li Z, Niu S, Liu J-M. Powerful inner/outer controlled multi-target magnetic nanoparticle drug carrier prepared by liquid photo-immobilization. Scientific reports. 2014;4(4990).
61.
Badruddoza AZM, Rahman MT, Ghosh S, Hossain MZ, Shi J, Hidajat K, et al. β-Cyclodextrin conjugated magnetic, fluorescent silica core–shell nanoparticles for biomedical applications. Carbohydr Polym. 2013;95(1):449–57.PubMed
62.
Erdal N, Gürgül S, Tamer L, Ayaz L. Effects of long-term exposure of extremely low frequency magnetic field on oxidative/nitrosative stress in rat liver. J Radiat Res. 2008;49(2):181–7.PubMed
63.
Qu J, Liu G, Wang Y, Hong R. Preparation of Fe3O4–chitosan nanoparticles used for hyperthermia. Adv Powder Technol. 2010;21(4):461–7.
64.
Viota J, Carazo A, Munoz-Gamez J, Rudzka K, Gómez-Sotomayor R, Ruiz-Extremera A, et al. Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation. Mater Sci Eng C. 2013;33(3):1183–92.
65.
Lee GY, Qian WP, Wang L, Wang YA, Staley CA, Satpathy M, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7(3):2078–89.PubMedPubMedCentral
66.
Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials. 2012;33(21):5414–22.PubMedPubMedCentral
67.
Hu H, Zhang C, An L, Yu Y, Yang H, Sun J, et al. General protocol for the synthesis of functionalized magnetic nanoparticles for magnetic resonance imaging from protected metal–organic precursors. Chem-A Europ J. 2014;20(23):7160–7.
68.
Sivakumar B, Aswathy RG, Sreejith R, Nagaoka Y, Iwai S, Suzuki M, et al. Bacterial exopolysaccharide based magnetic nanoparticles: a versatile nanotool for cancer cell imaging, targeted drug delivery and synergistic effect of drug and hyperthermia mediated cancer therapy. J Biomed Nanotechnol. 2014;10(6):885–99.PubMed
69.
Fazilati M. Folate decorated magnetite nanoparticles: synthesis and targeted therapy against ovarian cancer. Cell Biol Int. 2014;38(2):154–63.PubMed
70.
Mehrabi M, Javid A, Hashemi A, Rezaei-Zarchi S. Investigation of the effect of folic acid based iron oxide nanoparticles on human leukemic CCRF-CEM cell line. Iran J Pediatr Hematol Oncol. 2013;3(2):47–53.
71.
Gunduz U, Keskin T, Tansık G, Mutlu P, Yalcın S, Unsoy G, et al. Idarubicin-loaded folic acid conjugated magnetic nanoparticles as a targetable drug delivery system for breast cancer. Biomed Pharmacotherapy. 2014;68(6):729–36.
72.
An Q, Sun C, Li D, Xu K, Guo J, Wang C. Peroxidase-like activity of Fe3O4@ carbon nanoparticles enhances ascorbic acid-induced oxidative stress and selective damage to PC-3 prostate cancer cells. ACS Appl Mater Interfaces. 2013;5(24):13248–57.PubMed
73.
Li X, Ding J, Wang X, Wei K, Weng J, Wang J. One-pot synthesis and functionalisation of Fe 2 O 3@ CNH 2 nanoparticles for imaging and therapy. Nanobiotechnol, IET. 2014;8(2):93–101.
74.
Tang Z, Li D, Sun H, Guo X, Chen Y, Zhou S. Quantitative control of active targeting of nanocarriers to tumor cells through optimization of folate ligand density. Biomaterials. 2014;35(27):8015–27.PubMed
75.
Mikhaylova M, Kim DK, Bobrysheva N, Osmolowsky M, Semenov V, Tsakalakos T, et al. Superparamagnetism of magnetite nanoparticles: dependence on surface modification. Langmuir. 2004;20(6):2472–7.PubMed
76.
Kim J, Park S, Lee JE, Jin SM, Lee JH, Lee IS, et al. Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photothermal therapy. Angew Chem. 2006;118(46):7918–22.
77.
Wu W, Chen B, Cheng J, Wang J, Xu W, Liu L, et al. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine. 2010;5:1079.PubMedPubMedCentral
78.
Hervault A, Thanh NTK. Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment of cancer. Nanoscale. 2014;6(20):11553–73.PubMed
79.
Sivakumar Balasubramanian ARG, Nagaoka Y, Iwai S, Suzuki M, Kizhikkilot V, Yoshida Y, et al. Curcumin and 5-Fluorouracil-loaded, folate-and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. Int J Nanomedicine. 2014;9:437–59.PubMedPubMedCentral
80.
Chen B, Cheng J, Wu Y, Gao F, Xu W, Shen H, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine. 2009;4:73–8.PubMedPubMedCentral
81.
Chen B, Cheng J, Shen M, Gao F, Xu W, Shen H, et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int J Nanomedicine. 2009;4:65–71.PubMedPubMedCentral
82.
Goya G, Grazu V, Ibarra M. Magnetic nanoparticles for cancer therapy. Curr Nanosci. 2008;4(1):1–16.
83.
Safarik I, Safarikova M. Magnetically responsive nanocomposite materials for bioapplications. Solid State Phenom. 2009;151:88–94.
84.
Jeong U, Teng X, Wang Y, Yang H, Xia Y. Superparamagnetic colloids: controlled synthesis and niche applications. Adv Mater. 2007;19(1):33–60.
85.
Tang Q, Chen D. Study of the therapeutic effect of 188Re labeled folate targeting albumin nanoparticle coupled with cis-diamminedichloroplatinum cisplatin on human ovarian cancer. Bio-Med Mat Eng. 2014;24(1):711–22.
86.
Yoo H, Moon S-K, Hwang T, Kim YS, Kim J-H, Choi S-W, et al. Multifunctional magnetic nanoparticles modified with polyethylenimine and folic acid for biomedical theranostics. Langmuir. 2013;29(20):5962–7.PubMed
87.
Varshosaz J, Sadeghi-Aliabadi H, Ghasemi S, Behdadfar B. Use of magnetic folate-dextran-retinoic acid micelles for dual targeting of doxorubicin in breast cancer. BioMed Res Int. 2013;2013:680712.PubMedPubMedCentral
88.
Yang H-W, Hua M-Y, Liu H-L, Huang C-Y, Wei K-C. Potential of magnetic nanoparticles for targeted drug delivery. Nanotechnol Sci Appl. 2012;5:73–86.PubMedPubMedCentral
89.
Franckena M, Wit RD, Ansink AC, Notenboom A, Canters RA, Fatehi D, et al. Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int J Hyperth. 2007;23(5):443–50.
90.
Chen ZQ, Wen J, Tu WY, Xiao L, Fang Z. A study on early apoptosis of hepatoma Bel-7402 cells in vitro treated by altering-electric magnetic field exposure of extremely low frequency combined with magnetic nano-Fe3O4 powders. Appl Mech Mat. 2013;364:742–8.
91.
Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, et al. Mesostructured silica for optical functionality, nanomachines, and drug delivery. J Am Ceram Soc. 2009;92(s1):S2–S10.PubMedPubMedCentral
92.
Slowing II, Vivero-Escoto JL, Wu C-W, Lin VS-Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278–88.PubMed
93.
Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008;2(5):889–96.PubMedPubMedCentral
94.
Trewyn BG, Slowing II, Giri S, Chen H-T, Lin VS-Y. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol–gel process and applications in controlled release. Acc Chem Res. 2007;40(9):846–53.PubMed
95.
Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design a review. J Saudi Chem Soc. 2014;18(2):85–99.
96.
Kwon S, Singh RK, Perez RA, Neel EAA, Kim H-W, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. J Tiss Eng. 2013;4:2041731413503357.
97.
Wang S. Ordered mesoporous materials for drug delivery. Microporous Mesoporous Mater. 2009;117(1):1–9.
98.
Halamová D, Zeleňák V. NSAID naproxen in mesoporous matrix MCM-41: drug uptake and release properties. J Incl Phenom Macrocycl Chem. 2012;72(1-2):15–23.
99.
Ma X, Zhao Y, Ng KW, Zhao Y. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chem-A Europ J. 2013;19(46):15593–603.
100.
Fan J, Fang G, Wang X, Zeng F, Xiang Y, Wu S. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Nanotechnology. 2011;22(45):455102.PubMed
101.
Mohapatra S, Rout SR, Narayan R, Maiti TK. Multifunctional mesoporous hollow silica nanocapsules for targeted co-delivery of cisplatin-pemetrexed and MR imaging. Dalton Trans. 2014;43(42):15841–50.PubMed
102.
Luo Z, Ding X, Hu Y, Wu S, Xiang Y, Zeng Y, et al. Engineering a hollow nanocontainer platform with multifunctional molecular machines for tumor-targeted therapy in vitro and in vivo. ACS Nano. 2013;7(11):10271–84.PubMed
103.
Teng I, Chang Y-J, Wang L-S, Lu H-Y, Wu L-C, Yang C-M, et al. Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer. Biomaterials. 2013;34(30):7462–70.PubMed
104.
Jain S, Hirst D, O’sullivan J. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2014;85(1010):101–13.
105.
Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622–7.PubMed
106.
Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res. 2008;41(12):1842–51.PubMed
107.
Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114(3):343–7.PubMed
108.
Llevot A, Astruc D. Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancer. Chem Soc Rev. 2012;41(1):242–57.PubMed
109.
Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4(7):3689–96.PubMed
110.
Lin J, Zhou Z, Li Z, Zhang C, Wang X, Wang K, et al. Biomimetic one-pot synthesis of gold nanoclusters/nanoparticles for targeted tumor cellular dual-modality imaging. Nanoscale Res Lett. 2013;8(1):1–7.
111.
Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010;132(13):4678–84.PubMedPubMedCentral
112.
Jain PK, Huang W, El-Sayed MA. On the universal scaling behavior of the distance decay of plasmon coupling in metal nanoparticle pairs: a plasmon ruler equation. Nano Lett. 2007;7(7):2080–8.
113.
Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem. 2008;120(38):7394–8.
114.
Sezgin E, Karatas ÖF, Çam D, Sur İ, Sayin İ, Avci E, et al. Interaction of gold nanoparticles with living cells. Sigma. 2008;26:227–46.
115.
Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6(4):662–8.PubMed
116.
De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29(12):1912–9.PubMed
117.
Semmler‐Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, et al. Biodistribution of 1.4 and 18 nm gold particles in rats. Small. 2008;4(12):2108–11.PubMed
118.
Pandey S, Mewada A, Thakur M, Shah R, Oza G, Sharon M. Biogenic gold nanoparticles as fotillas to fire berberine hydrochloride using folic acid as molecular road map. Mater Sci Eng C. 2013;33(7):3716–22.
119.
Park J, Jeon WI, Lee SY, Ock KS, Seo JH, Park J, et al. Confocal Raman microspectroscopic study of folate receptor targeted delivery of 6 mercaptopurine embedded gold nanoparticles in a single cell. J Biomed Mat Res Part A. 2012;100(5):1221–8.
120.
Ganeshkumar M, Ponrasu T, Raja MD, Subamekala MK, Suguna L. Green synthesis of pullulan stabilized gold nanoparticles for cancer targeted drug delivery. Spectrochim Acta A Mol Biomol Spectrosc. 2014;130:64–71.PubMed
121.
Zhu J, Zheng L, Wen S, Tang Y, Shen M, Zhang G, et al. Targeted cancer theranostics using alpha-tocopheryl succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles. Biomaterials. 2014;35(26):7635–46.PubMed
122.
Kattumuri V, Katti K, Bhaskaran S, Boote EJ, Casteel SW, Fent GM, et al. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: in vivo pharmacokinetics and x-ray contrast imaging studies. Small. 2007;3(2):333–41.PubMed
123.
Fent GM, Casteel SW, Kim DY, Kannan R, Katti K, Chanda N, et al. Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. Nanomed: Nanotechnol, Biol Med. 2009;5(2):128–35.
124.
Triulzi RC, Dai Q, Zou J, Leblanc RM, Gu Q, Orbulescu J, et al. Photothermal ablation of amyloid aggregates by gold nanoparticles. Colloids Surf B: Biointerfaces. 2008;63(2):200–8.PubMed
125.
Jain PK, El-Sayed IH, El-Sayed MA. Au nanoparticles target cancer. Nano Today. 2007;2(1):18–29.
126.
Mehdizadeh A, Pandesh S, Shakeri-Zadeh A, Kamrava SK, Habib-Agahi M, Farhadi M, et al. The effects of folate-conjugated gold nanorods in combination with plasmonic photothermal therapy on mouth epidermal carcinoma cells. Lasers Med Sci. 2014;29(3):939–48.PubMed
127.
Hu D, Sheng Z, Fang S, Wang Y, Gao D, Zhang P, et al. Folate receptor-targeting gold nanoclusters as fluorescence enzyme mimetic nanoprobes for tumor molecular colocalization diagnosis. Theranostics. 2014;4(2):142.PubMedPubMedCentral
128.
Xu S, Liu J, Wang T, Li H, Miao Y, Liu Y, et al. A simple and rapid electrochemical strategy for non-invasive, sensitive and specific detection of cancerous cell. Talanta. 2013;104:122–7.PubMed
129.
Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1–7.PubMedPubMedCentral
130.
Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker Jr JR. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharmaceut Sci Technol. 2000;3(7):232–45.
131.
Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005;10(1):35–43.PubMed
132.
Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker Jr JR, Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007;14(1):107–15.PubMed
133.
Myc A, Douce TB, Ahuja N, Kotlyar A, Kukowska-Latallo J, Thomas TP, et al. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anti-Cancer Drugs. 2008;19(2):143–9.PubMed
134.
Kesharwani P, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm Res. 2014;32(4):1438–50.PubMed
135.
Birdhariya B, Kesharwani P, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev Indust Pharma. 2014(0):1-7.
136.
Wong PT, Tang K, Coulter A, Tang S, Baker Jr JR, Choi SK. Multivalent dendrimer vectors with DNA intercalation motifs for gene delivery. Biomacromolecules. 2014;15(11):4134–45.PubMed
137.
Arima H, Arizono M, Higashi T, Yoshimatsu A, Ikeda H, Motoyama K, et al. Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells. Cancer Gene Ther. 2012;19(5):358–66.PubMed
138.
Wang M, Hu H, Sun Y, Qiu L, Zhang J, Guan G, et al. A pH-sensitive gene delivery system based on folic acid-PEG-chitosan–PAMAM-plasmid DNA complexes for cancer cell targeting. Biomaterials. 2013;34(38):10120–32.PubMed
139.
Sunoqrot S, Bugno J, Lantvit D, Burdette JE, Hong S. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Control Release. 2014;191:115–22.PubMedPubMedCentral
140.
Liu W, Sun S, Cao Z, Zhang X, Yao K, Lu WW, et al. An investigation on the physicochemical properties of chitosan/DNA polyelectrolyte complexes. Biomaterials. 2005;26(15):2705–11.PubMed
141.
Sadigh-Eteghad S, Talebi M, Farhoudi M, Mahmoudi J, Reyhani B. Effects of Levodopa loaded chitosan nanoparticles on cell viability and caspase-3 expression in PC12 neural like cells. Neurosciences. 2013;18(3):281–3.PubMed
142.
143.
Xu Q, Wang C-H, Pack DW. Polymeric carriers for gene delivery: chitosan and poly (amidoamine) dendrimers. Curr Pharm Des. 2010;16(21):2350.PubMedPubMedCentral
144.
Song H, Su C, Cui W, Zhu B, Liu L, Chen Z, et al. Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery. BioMed Res Int. 2013;2013.
145.
Pramanik A, Laha D, Pramanik P, Karmakar P. A novel drug “copper acetylacetonate” loaded in folic acid-tagged chitosan nanoparticle for efficient cancer cell targeting. J Drug Target. 2013;22(1):23–33.PubMed
146.
Zhou J, Wang J, Xu Q, Xu S, Wen J, Yu Z, et al. Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer. Chin J Cancer Res. 2013;25(5):527.PubMedPubMedCentral
147.
Zheng Y, Cai Z, Song X, Yu B, Bi Y, Chen Q, et al. Receptor mediated gene delivery by folate conjugated N-trimethyl chitosan in vitro. Int J Pharm. 2009;382(1):262–9.PubMed
148.
Lee KD, Choi S-H, Kim DH, Lee H-Y, Choi K-C. Self-organized nanoparticles based on chitosan-folic acid and dextran succinate-doxorubicin conjugates for drug targeting. Arch Pharmacal Res. 2014:1-8.
149.
Gaspar VM, Costa EC, Queiroz JA, Pichon C, Sousa F, Correia IJ. Folate-targeted multifunctional amino acid-chitosan nanoparticles for improved cancer therapy. Pharm Res. 2014;1–16.
150.
Jia M, Li Y, Yang X, Huang Y, Wu H, Huang Y, et al. Development of both methotrexate and mitomycin C loaded pegylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect. ACS Appl Mater Interfaces. 2014;6(14):11413–23.PubMed
151.
Shi Z, Guo R, Li W, Zhang Y, Xue W, Tang Y, et al. Nanoparticles of deoxycholic acid, polyethylene glycol and folic acid-modified chitosan for targeted delivery of doxorubicin. J Mater Sci Mater Med. 2014;25(3):723–31.PubMed
152.
Li TSC, Yawata T, Honke K. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid–poly (ethylene glycol)–chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Eur J Pharm Sci. 2014;52:48–61.PubMed
153.
Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1995;123(2):99–108.
154.
Liu Y, Li K, Pan J, Liu B, Feng S-S. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 2010;31(2):330–8.PubMed
155.
Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–6.PubMed
156.
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60.PubMed
157.
Tong R, Cheng J. Anticancer polymeric nanomedicines. J Macromol Sci Polym Rev. 2007;47(3):345–81.
158.
S-s F, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J Control Release. 2001;71(1):53–69.
159.
Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA: Cancer J Clin. 2008;58(2):97–110.
160.
Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 1991;51(19):5329–38.PubMed
161.
Zhang Z, Jia J, Lai Y, Ma Y, Weng J, Sun L. Conjugating folic acid to gold nanoparticles through glutathione for targeting and detecting cancer cells. Bioorg Med Chem. 2010;18(15):5528–34.PubMed
162.
Ai J, Xu Y, Li D, Liu Z, Wang E. Folic acid as delivery vehicles: targeting folate conjugated fluorescent nanoparticles to tumors imaging. Talanta. 2012;101:32–7.PubMed
163.
Zhu Y, Cheng L, Cheng L, Huang F, Hu Q, Li L, et al. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo. Pharm Res. 2014;31(12):3289–303.PubMed
Metadata
Title
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy
Authors
Behdokht Bahrami
Mousa Mohammadnia-Afrouzi
Peyman Bakhshaei
Yaghoub Yazdani
Ghasem Ghalamfarsa
Mehdi Yousefi
Sanam Sadreddini
Farhad Jadidi-Niaragh
Mohammad Hojjat-Farsangi
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3706-6

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

Antagomir-1290 suppresses CD133+ cells in non-small cell lung cancer by targeting fyn-related Src family tyrosine kinase

Research Article

C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn

Research Article

miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4

Research Article

Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2

Research Article

Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma

Research Article

Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits